blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1427855

EP1427855 - METHOD AND REAGENTS FOR IDENTIFYING GENE TARGETS FOR TREATING BREAST CANCER [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  19.06.2009
Database last updated on 09.09.2024
Most recent event   Tooltip19.06.2009Application deemed to be withdrawnpublished on 22.07.2009  [2009/30]
Applicant(s)For all designated states
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
352 Henry Administration Building
506 South Wright Street
Urbana, IL 61801 / US
[N/P]
Former [2004/25]For all designated states
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
352 Henry Administration Building, 506 South Wright Street
Urbana, Illinois 61801 / US
Inventor(s)01 / PRIMIANO, Thomas
Suite 2619, 211 E.Ohio St.
Chicago, IL 60611 / US
02 / CHANG, Bey-Dih
1116 Cambria Lane
Lombard, IL 60148 / US
03 / RONINSON, Igor, B.
2731 Lincoln Lane
Wilmette, IL 60091 / US
 [2004/25]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstrasse 4
80802 München / DE
[N/P]
Former [2004/25]Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät
Maximilianstrasse 58
80538 München / DE
Application number, filing date02761122.719.07.2002
[2004/25]
WO2002US22868
Priority number, dateUS20010306730P20.07.2001         Original published format: US 306730 P
WO2002US0625428.02.2002         Original published format: PCT/US02/06254
[2004/25]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO03007884
Date:30.01.2003
Language:EN
[2003/05]
Type: A2 Application without search report 
No.:EP1427855
Date:16.06.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 30.01.2003 takes the place of the publication of the European patent application.
[2004/25]
Search report(s)International search report - published on:US20.11.2003
(Supplementary) European search report - dispatched on:EP28.02.2005
ClassificationIPC:C12N15/10, C12Q1/68, C07K14/00, A61P43/00
[2004/52]
CPC:
C07K7/08 (EP,US); A61P35/00 (EP); A61P43/00 (EP);
C07K14/47 (EP,US); C12Q1/6886 (EP,US); G01N33/5011 (EP,US);
G01N33/5023 (EP,US); G01N33/57415 (EP,US); A61K38/00 (EP,US);
C12Q2600/158 (EP,US); G01N2500/10 (EP,US); G01N2800/52 (EP,US) (-)
Former IPC [2004/25]C12Q1/68
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2004/25]
Extension statesAL20.02.2004
LT20.02.2004
LV20.02.2004
MK20.02.2004
RO20.02.2004
SI20.02.2004
TitleGerman:VERFAHREN UND REAGENZIEN ZUR IDENTIFIZIERUNG VON GEN-ZIELMOLEKÜLEN ZUR BEHANDLUNG VON BRUSTKREBS[2004/25]
English:METHOD AND REAGENTS FOR IDENTIFYING GENE TARGETS FOR TREATING BREAST CANCER[2004/25]
French:PROCEDES ET DES REACTIFS D'IDENTIFICATION DES GENES CIBLES EN VUE DU TRAITEMENT DU CANCER DU SEIN[2004/25]
Entry into regional phase20.02.2004National basic fee paid 
20.02.2004Search fee paid 
20.02.2004Designation fee(s) paid 
20.02.2004Examination fee paid 
Examination procedure20.02.2004Amendment by applicant (claims and/or description)
20.02.2004Examination requested  [2004/25]
31.01.2006Despatch of a communication from the examining division (Time limit: M06)
10.08.2006Reply to a communication from the examining division
03.02.2009Application deemed to be withdrawn, date of legal effect  [2009/30]
06.03.2009Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2009/30]
Fees paidRenewal fee
22.07.2004Renewal fee patent year 03
20.07.2005Renewal fee patent year 04
27.07.2006Renewal fee patent year 05
27.07.2007Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.07.200807   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]EP0881300  (CELL PATHWAY INC [US]) [A] 1-21 * abstract * * page 7, line 22 - line 55 *;
 [A]US5998136  (KAMB CARL ALEXANDER [US]) [A] 1-21 * abstract * * column 34, line 42 - line 58 * * column 37, line 1 - line 25 *;
 [Y]WO0055174  (HUMAN GENOME SCIENCES INC [US], et al) [Y] 1-21 * SeqIdNos 356, 1296 * * abstract * * page 12, line 1 - line 6 * * page 41 * * page 271 * * page 355 * * page 414, line 28 - page 415, line 16 * * page 420 - page 421 * * page 493, line 7 - line 18 *;
 [Y]WO0123617  (NAT JEWISH MED & RES CENTER [US]) [Y] 1-21 * abstract * * page 6, line 22 - page 7, line 15 * * page 9, line 23 - page 10, line 28 * * claims 28-30,33,37-47 *;
 [A]WO0140464  (GENENTECH INC [US], et al) [A] 1-21* abstract *;
 [Y]  - TALUKDER AMJAD H ET AL, "Heregulin induces expression, DNA binding activity, and transactivating functions of basic leucine zipper activating transcription factor 4", CANCER RESEARCH, (20000115), vol. 60, no. 2, ISSN 0008-5472, pages 276 - 281, XP002302778 [Y] 1-21 * page 276, column R, line 40 - line 45 *
 [A]  - UENO N T ET AL, "GROWTH SUPPRESSION OF LOW HER-2/NEU-EXPRESSING BREAST CANCER CELL LINE MDA-MB-435 BY TYROSINE KINASE INHIBITOR EMODIN", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, (19960501), vol. 3, no. 3, ISSN 1021-335X, pages 509 - 511, XP000672384 [A] 1-21 * page 509 *
International search[A]US5512660  (SPRINGER TIMOTHY ALAN [US], et al);
 [A]US5837488  (GARFINKEL LEONARD [IL], et al);
 [A]US5969124  (LEMMON VANCE [US])
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.